Skip to main content
Medical Reference · Condition Monograph

Liver cancer

간암

There are several kinds of disease called liver cancer, but the most common primary liver cancer in adults is hepatocellular carcinoma.

History

There are several kinds of disease called liver cancer, but the most common primary liver cancer in adults is hepatocellular carcinoma. Hepatocellular carcinoma is a cancer that begins in hepatocytes, the basic cells that make up the liver, and most cases arise against a background of chronic liver disease and liver cirrhosis. In the past, it was often discovered only after symptoms such as jaundice, ascites, and severe weight loss had appeared, so many patients already had advanced disease at the time of diagnosis. Because the liver is "an organ in which symptoms appear late," liver cancer has historically been regarded as a cancer with a poor prognosis.

A major turning point in the history of hepatocellular carcinoma came as understanding of its causes deepened. As it was established that viral hepatitis such as hepatitis B and hepatitis C can cause liver cirrhosis and liver cancer, liver cancer came to be characterized as "a cancer linked to the management of infectious disease." The spread of the hepatitis B vaccine and advances in antiviral treatment have led to a reduction in the burden of virus-related liver cancer in some regions. On the other hand, as lifestyle-related and metabolic diseases have increased, the view that fatty liver and metabolic abnormalities can be an important background for liver cancer has also grown.

In terms of diagnosis, advances in imaging technologies such as ultrasound, computed tomography, and magnetic resonance imaging were decisive. Unlike many other cancers, hepatocellular carcinoma can be diagnosed by imaging alone without a biopsy under certain conditions, and this changed the clinical workflow. Recent research shows that the combination of immunotherapy and targeted therapy is changing the standard treatment for advanced hepatocellular carcinoma and is developing in a direction that greatly increases treatment options.

Causes

Most causes of hepatocellular carcinoma can be summarized as "chronic liver injury." Hepatocellular carcinoma usually arises on top of the scarring changes of liver cirrhosis, and diseases that can cause liver cirrhosis therefore raise the risk of liver cancer. Representative causes are chronic hepatitis B, chronic hepatitis C, and alcohol-related liver disease due to heavy drinking.

Recently, nonalcoholic fatty liver disease and its progressive form, steatohepatitis, have emerged as important causes. Metabolic abnormalities such as obesity, diabetes, and hyperlipidemia worsen fatty liver and can lead to liver fibrosis and liver cirrhosis, raising the risk of hepatocellular carcinoma. Especially in regions where viral hepatitis is decreasing, metabolic disease and alcohol-related liver disease are discussed as the main factors explaining the increase in liver cancer. In addition, exposure to fungal toxins (aflatoxin), smoking, and some genetic and metabolic diseases are mentioned as risk factors.

The important point is that "hepatocellular carcinoma mostly occurs in people whose liver is already damaged, and the risk can be lowered by managing the causes." In other words, it is more accurate to understand the causes of hepatocellular carcinoma as the result of the long-term accumulation of lifestyle, infection, and metabolic status.

Genetic Epidemiology

The genetic epidemiology of hepatocellular carcinoma is somewhat different in character from that of other cancers. Most hepatocellular carcinomas arise not from a strong single-gene disease but from the long-term action of environmental and lifestyle factors such as viral hepatitis, alcohol, and metabolic disease. However, because the rate of progression to liver cirrhosis and the risk of progression to cancer differ from person to person even with exposure to the same risk factors, the possibility that host (individual) genetic predisposition modulates the risk has been continuously studied.

Some genetic and metabolic diseases can markedly raise the risk of hepatocellular carcinoma. For example, diseases in which iron accumulates excessively in the liver and certain metabolic abnormalities promote chronic liver injury and liver cirrhosis, increasing the risk of cancer. In addition, the observation that a family history raises the risk of liver cancer may reflect not only genetic factors but also the influence of infections shared within a family (for example, transmission of hepatitis B within a family), drinking habits, and dietary habits.

Recent research has increasingly reported that genetic variants can help distinguish risk in fatty liver-related liver cancer, and attempts to stratify risk with blood-based biomarker panels are continuing. For the general public at present, the key point is that "lifestyle and chronic liver disease factors explain most hepatocellular carcinoma, and in certain metabolic and genetic diseases the risk is especially high, requiring separate follow-up."

General Epidemiology

Hepatocellular carcinoma accounts for a large share of cancer deaths worldwide. Because the distribution of risk factors differs by region, the incidence also varies greatly. In regions where viral hepatitis is common, the burden of hepatocellular carcinoma is high, and as vaccination and antiviral treatment expand, a decrease in that burden is observed. Conversely, in some regions, including high-income countries, a trend of increasing hepatocellular carcinoma is discussed as metabolic disease (fatty liver) and alcohol-related liver disease increase.

Most patients with hepatocellular carcinoma also have liver cirrhosis. In other words, not only the stage of the liver cancer itself but also liver function (for example, jaundice, ascites, and abnormal blood clotting) greatly affects treatment choices and prognosis. Therefore, hepatocellular carcinoma is a representative cancer in which "treatment of the cancer" and "treatment of the liver disease" must be considered at the same time.

Recent research shows that surveillance of high-risk groups (such as regular ultrasound) can increase early diagnosis and improve treatment outcomes, but it is repeatedly pointed out that in reality surveillance is not carried out sufficiently. In particular, patients with fatty liver are often not recognized as a high-risk group, and obesity reduces the sensitivity of ultrasound, so improving the surveillance system is mentioned as a task to be addressed.

Pathogenesis

Hepatocellular carcinoma develops in an environment of repeated chronic inflammation and tissue regeneration. When the liver is damaged by viral infection, alcohol, steatohepatitis, and so on, inflammation persists and hepatocytes keep dividing to repair the damage. In this process, DNA damage accumulates, and as mutations and epigenetic changes build up, the likelihood of progression to cancer cells increases. Liver cirrhosis is close to the "final common pathway" of this process, and its structure of repeated fibrosis and nodular regeneration itself creates an environment that promotes cancer development.

Hepatitis B holds a special place in the pathogenesis of hepatocellular carcinoma. It has long been discussed that it not only raises the risk of liver cancer through liver cirrhosis but that the process by which viral genetic material is inserted into the host genome can create genetic instability. For hepatitis C, the pathway of raising the risk mainly through chronic inflammation and liver cirrhosis is emphasized.

Recent research has proposed a model in which insulin resistance, fat accumulation, oxidative stress, the gut-liver axis (gut microbes and their metabolites), and changes in the immune environment can act in combination in fatty liver-related liver cancer. In addition, angiogenesis and immune evasion in the tumor microenvironment can determine treatment response, providing a background that explains why immunotherapy is effective in some patients and limited in others.

Symptoms

Hepatocellular carcinoma often has no symptoms in the early stage. Therefore, early liver cancer found during surveillance of high-risk groups is usually asymptomatic. When symptoms develop, there may be discomfort or pain in the upper right part of the abdomen, loss of appetite, weight loss, and a feeling of getting tired easily. Nausea, vomiting, and a feeling of abdominal bloating may also accompany these.

Because hepatocellular carcinoma often develops in people who already have chronic liver disease, cancer symptoms and symptoms of worsening liver cirrhosis may appear mixed together. For example, there may be changes such as a sudden increase in ascites (fluid accumulating in the abdomen), worsening jaundice, or bruising and bleeding more easily than before.

In advanced cases, the mass may grow large enough to be felt, the tumor may block blood vessels and cause severe abdominal pain, or complications such as bleeding from gastric or esophageal varices may occur. If it spreads to other organs, symptoms such as bone pain or shortness of breath may develop, but in hepatocellular carcinoma, worsening liver function often affects quality of life and survival more directly than metastasis.

Signs

The signs that can be observed on examination overlap with the signs of liver disease. There may be findings of chronic liver disease such as jaundice, ascites, leg edema, spider angiomas, and palmar erythema. The liver may be enlarged and palpable, or if the tumor is large, a mass may be felt in the upper abdomen.

Important signs in testing are imaging findings. When a liver nodule is found by ultrasound in a high-risk patient, the diagnosis is often made by confirming a characteristic blood flow pattern with multiphase computed tomography or magnetic resonance imaging. In blood tests, alpha-fetoprotein is elevated in some patients and helps with diagnosis and follow-up, but it is not elevated in all patients and can also rise with hepatitis activity or other diseases.

Liver function tests (bilirubin, albumin, coagulation indicators, etc.) are key data for determining treatment options. Because in hepatocellular carcinoma liver function often limits treatment choices more than the cancer itself, staging considers both "the extent of the cancer" and "the reserve capacity of the liver."

Screening

Screening (surveillance) for hepatocellular carcinoma targets high-risk groups rather than the entire average-risk population. High-risk groups include patients with liver cirrhosis, patients with chronic hepatitis B (especially those with high-risk conditions), and some patients with chronic hepatitis C. In general, liver ultrasound is performed at 6-month intervals, and in some cases an alpha-fetoprotein blood test is performed at the same time.

Recent research discusses that combining ultrasound and alpha-fetoprotein can increase the sensitivity of early liver cancer detection, but that recommendations are not consistent because alpha-fetoprotein can increase false positives. In addition, in patients with obesity or fatty liver, lesions may not be seen well on ultrasound, reducing sensitivity. To make up for these problems, alternatives such as blood-based biomarker panels and abbreviated magnetic resonance imaging are being studied.

What matters in surveillance is not "having the test once" but "having it consistently at set intervals." In actual clinical practice, low participation in surveillance often leads to missed opportunities for early diagnosis, so there is repeated discussion of the need for system improvements such as patient guidance, appointment systems, and reminders for medical staff.

Diagnosis

The diagnosis of hepatocellular carcinoma usually proceeds in the sequence "detection of a nodule in a high-risk patient → confirmation of its characteristics with multiphase imaging → biopsy if necessary." A characteristic feature of hepatocellular carcinoma is that it can be diagnosed by imaging findings alone under certain conditions. If a typical blood flow pattern is seen on multiphase computed tomography or multiphase magnetic resonance imaging, a biopsy can be omitted.

A biopsy is considered when imaging findings are ambiguous, when a liver mass is found in a person who is not in a high-risk group, or when it needs to be distinguished from other liver tumors. In addition, to assess the extent of the tumor, vascular invasion, invasion of the portal vein (the large blood vessel entering the liver), and metastasis outside the liver are checked.

Staging is the core of treatment planning. The widely used staging systems for hepatocellular carcinoma include not only "tumor size and metastasis" but also "liver function" and "general condition." Therefore, immediately after diagnosis, a multidisciplinary judgment is made that includes liver function assessment (Child–Pugh, etc.), whether the patient is in a condition to tolerate treatment, and even whether the patient may be a candidate for liver transplantation.

Treatment

Treatment of hepatocellular carcinoma varies depending on the stage, the location and number of tumors, vascular invasion, liver function, and general condition. In the early stage, treatment aimed at cure is possible. Surgical liver resection is chosen when liver function is sufficient and the tumor is resectable. Liver transplantation holds an important place as a treatment that can "resolve the cancer and liver cirrhosis at the same time" in patients whose tumors are within certain limits and whose liver function is poor. When surgery is difficult or the tumor is small, local ablation such as radiofrequency ablation may be used.

In the intermediate stage, locoregional liver treatments such as transarterial chemoembolization are widely used. This approach controls the tumor by blocking the blood flow to the tumor or selectively injecting drugs. In some patients, a strategy of "downstaging" the tumor by shrinking it with treatment so that the patient becomes a candidate for surgery or liver transplantation is considered.

In the advanced stage, systemic treatment becomes central. Recent research has led to the combination of immune checkpoint inhibitors and anti-angiogenic therapy taking an important place in first-line treatment, and there is a trend toward expanding combinations of targeted therapy and immunotherapy in later lines as well. However, because liver function can limit the drugs used in hepatocellular carcinoma, not only the effectiveness of a drug but also how much it worsens liver function must be considered.

Prognosis

The prognosis of hepatocellular carcinoma is determined jointly by "how advanced the cancer is" and "liver function." Even with a tumor of the same size, if liver function is poor, surgery or intensive treatment may be difficult, and the prognosis may differ. If it is detected early and treatments such as resection, liver transplantation, or local ablation are possible, cure or long-term survival can be expected.

However, many patients have a background of liver cirrhosis, and in some cases there are already multiple lesions or vascular invasion at diagnosis, limiting treatment. Recent research reports a trend of improved survival as early detection increases through surveillance programs, and with the development of immunotherapy-based systemic treatment, cases of prolonged survival are increasing even in advanced disease.

When discussing prognosis, quality of life is also important. When complications of liver cirrhosis such as ascites, hepatic encephalopathy, bleeding, and infection recur, the treatment process becomes difficult and hospitalizations and procedures may become frequent. Therefore, in the treatment of hepatocellular carcinoma, management that preserves liver function and prevents complications is essential along with treatment of the tumor.

Prevention

For the prevention of hepatocellular carcinoma, "managing the causes" is clearer than for many other cancers. The most important prevention is hepatitis B vaccination. For those who already have hepatitis B or hepatitis C, suppressing the hepatitis with antiviral treatment and slowing the progression of liver cirrhosis is the key to reducing the risk of liver cancer. Reducing alcohol intake and correcting drinking habits that cause liver cirrhosis are also important.

Prevention related to metabolic disease is also growing in importance. Lifestyle habits that control obesity and diabetes and improve fatty liver (weight loss, regular exercise, a balanced diet) are understood to slow the progression of liver fibrosis and lower the risk of liver cancer. Recent research emphasizes the importance of a strategy of identifying high-risk groups among patients with fatty liver and strengthening their surveillance.

Another form of prevention is surveillance, which is "secondary prevention." For those in high-risk groups, such as people with liver cirrhosis or chronic hepatitis B, consistently undergoing ultrasound at 6-month intervals (including blood tests if necessary) for early detection is in practice one of the most effective prevention strategies. Ultimately, the prevention of hepatocellular carcinoma can be summarized as vaccination, antiviral treatment, lifestyle correction, and regular surveillance of high-risk groups.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.